← Leaderboards
Hillel Grossman
Mount Sinai School Of Medicine Of Nyu
$9,146,815
Attributed
$9,470,623
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,470,623 · 10
By mechanism
P30$6,172,302 · 2
P50$1,854,032 · 1
R21$1,312,495 · 2
M01$131,794 · 5
Top collaborators
- Samuel E Gandy3 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Giulio Maria Pasinetti$21,413,515
- Thomas W Mittag$3,871,776
- Srinivas Ravi V Iyengar$36,509,089
- Tibor Rohacs$10,344,932
- Charles S Lieber$6,244,965
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposResearch PersonnelS DiseaseBrainClinical ResearchCognitiveResourcesClinical TrialsDementiaBiological MarkersImpaired CognitionDesignElderlyUnited States National Institutes Of HealthNeuroimagingInstitutionSpecimenEvaluationBiologicalData CollectionProgramsFollow-UpNeuropathologyMild Cognitive Impairment
Grant awards (23)
Core B - Clinical Core$952,952
P30 · FY2025 · AG · contact PI
Clinical Core$797,102
P30 · FY2024 · AG · contact PI
Clinical Core$1,007,478
P30 · FY2023 · AG · contact PI
Clinical Core$1,358,844
P30 · FY2022 · AG · contact PI
Clinical Core$1,239,509
P30 · FY2021 · AG · contact PI
Clinical Core$816,417
P30 · FY2020 · AG · contact PI
Core B - Clinical$413,423
P50 · FY2019 · AG · contact PI
Core B - Clinical$418,151
P50 · FY2018 · AG · contact PI
Core B - Clinical$340,567
P50 · FY2017 · AG · contact PI
Core B - Clinical$341,326
P50 · FY2016 · AG · contact PI
Core B - Clinical$340,565
P50 · FY2015 · AG · contact PI
Phase 11-Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease$164,415
R21 · FY2014 · AT
Phase 11-Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease$241,601
R21 · FY2012 · AT
Phase 11-Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease$241,601
R21 · FY2010 · AT
DEVELOPMENT OF D-PINITOL IN THE TREATMENT OF ALZHEIMER'S DISEASE$17,372
M01 · FY2009 · RR · contact PI
Pilot studies of the nutritional supplement d-pinitol in Alzheimer's Disease$161,293
R21 · FY2008 · AT · contact PI
DEVELOPMENT OF D-PINITOL IN THE TREATMENT OF ALZHEIMER'S DISEASE$101,019
M01 · FY2008 · RR · contact PI
ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE$1,142
M01 · FY2008 · RR · contact PI
Pilot studies of the nutritional supplement NIC5-15 in Alzheimers Disease$164,585
R21 · FY2007 · AT · contact PI
ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE$1,824
M01 · FY2007 · RR · contact PI
Pilot studies of the nutritional supplement d-pinitol in Alzheimer's Disease$339,000
R21 · FY2006 · AT · contact PI
A TRIAL OF AN INSULIN-SENSITIVITY ENHANCING AGENT TO IMPROVE COGNITIVE OUTCOM$3,624
M01 · FY2005 · RR
A Trial of an Insulin-Sensitivity Enhancing Agent to Improve Cognitive Outcom...$6,813
M01 · FY2004 · RR